Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Cancer Predisposition
•
BRCA+
•
Breast Cancer, Non-metastatic
Is it safe to use hormone replacement therapy in young premenopausal patients with BRCA1 mutation, triple negative breast cancer, who have undergone bilateral mastectomies and BSO without hysterectomy?
Related Questions
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?
What recommendations would you make for a patient on long term phenytoin due to epilepsy with a newly diagnosed breast cancer requiring doxorubicin as part of her chemotherapy?
How do you treat inflammatory breast cancer (HR+, HER2 1+) treated with NAC (ACT) and mastectomy, with multifocal subcentimeter residual disease that on retesting is HR+, HER 2 2+ FISH amplified?
Is there a role for adjuvant pembrolizumab/capecitabine in a patient with TNBC who receives neoadjuvant AC-T with residual disease found at time of surgery?
Would you give AC followed by Taxol or TC for luminal type B, clinical high risk, breast cancer?
What is your treatment approach in a patient with cT2 ER+HER2+ who refuses neoadjuvant chemotherapy?
What would you recommend regarding IVF in a patient with DCIS on tamoxifen dealing with infertility?”
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
